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Abstract
The cytokine interleukin-1 (IL-1) is a key contributor to neuroinflammation and brain injury, yet mechanisms by which IL-1 triggers neuronal injury remain unknown. Here 
Background
Inflammation is a major contributor to stroke pathophysiology and is therefore an attractive therapeutic target. A key mediator of inflammation is the pro-inflammatory cytokine interleukin-1 (IL-1) (1). IL-1, expressed as two isoforms IL-1 and IL-1, is upregulated rapidly after experimental cerebral ischaemia and very early expression is thought to occur in monocyte and macrophage lineages, whilst slightly delayed expression occurs in astrocytes, neurons, endothelial cells and invading immune cells (2) (3) (4) . Preclinical studies using experimental animal models have demonstrated the importance of IL-1 in stroke. Central or systemic administration of exogenous recombinant IL-1 in rodents subjected to middle cerebral artery occlusion (MCAo) exacerbates brain damage (5-7), whilst disruption of both IL-1 and IL-1 in IL-1/ knockout (KO) mice results in a 70% reduction in infarct volume (8) .
There is extensive experimental evidence showing that blockade of IL-1 signalling using the IL-1 receptor antagonist (IL-1Ra) is protective in stroke and other forms of brain injury, and early stage clinical trials of IL-1Ra in both ischaemic and haemorrhagic stroke have to date shown potentially promising results (9) . However, the cellular mechanisms by which IL-1 mediates brain injury following cerebral ischaemia remain unknown.
IL-1 is known to exert its actions via binding and activation of its main functional IL-1 type 1 receptor (IL-1R1) (10) . IL-1R1 is expressed on the cerebrovasculature (11) and in vitro studies also suggest that IL-1 acts in the brain through endothelial cells (12, 13) , whilst toxic actions of IL-1 are mediated via cerebrovascular activation and transmigration of neutrophils (14) in vitro.
The knockdown of endothelial IL-1R1 has been investigated in vivo (15, 16) but has been focussed on ubiquitous knockdown rather than inhibiting specific endothelial cell subsets, such as in the brain. IL-1 acts both peripherally and centrally (17) but precise brain specific actions
have not yet been identified. IL-1 also has diverse actions on neurons, including fast electrophysiological firing (18, 19) , potentiation of excitotoxicity and changes in neuronal gene expression (4, 20) . However, functional data showing the effect of IL-1 on neurons and endothelial cells have been obtained only from in vitro studies (21, 22) , including our previous work showing IL-1 acts on neurons to produce inflammatory mediators (23) , suggesting neuronal signalling could contribute to detrimental neuroinflammatory responses, though the contribution of cell specific IL-1 actions to brain injury in vivo remains unknown.
The objective of this study was to determine the target cells of IL-1 action during ischaemic brain injury in mice. Tools to selectively and conditionally delete IL-1R1 in different cell types in vivo have become available recently (24, 25) . Thus, we investigated the contribution of endothelial cells and neurons to ischaemic brain injury by deleting IL-1R1 from brain endothelial cell or neurons (including cholinergic neuronal cells). We also assessed the effects of IL-1R1 deficiency in platelets and myeloid cells, cell types that are known to contribute to diverse forms of brain injury and that are involved in systemic IL-1 actions (26-28). We show that both brain endothelial and neuronal IL-1R1 mediate the actions of IL-1 on brain injury via functionally distinct mechanisms, some of which (i.e. effects on cerebral perfusion) are apparent in the first hour after the ischaemic insult. We also reveal that IL-1R1 on cholinergic neurons themselves represent a potential therapeutic target against the detrimental effects of IL-1 after acute brain injury.
Materials and Methods

Experimental Design
Animal procedures were carried out in accordance with the Animal Scientific Procedures Act there were 23 mice excluded from the study, which is 14.6% of the total used.
Focal cerebral ischaemia
Anaesthesia was induced by inhalation of 4% isoflurane (30% oxygen and 70% nitrous oxide gas mix, AbbVie Ltd, UK or Linde Ltd, Hungary) and was maintained at 1.75%. Body temperature was monitored throughout surgery (via rectal probe) and maintained at 37°C ± 0.5°C using a heating blanket (Harvard Apparatus, Edenbridge, Kent, UK). A laser Doppler blood flow monitor (Oxford Optronix, Abingdon, UK) was used to monitor cerebral blood flow (CBF). Focal cerebral ischaemia was induced by MCAo based on a previously described protocol (33). Briefly, a hole was made into the temporalis muscle (6 mm lateral and 2 mm posterior from bregma) to allow a 0.5 mm diameter flexible laser-Doppler probe to be fixed onto the skull and secured in place by tissue adhesive (Vetbond, UK). A midline incision was made on the ventral surface of the neck and the right common carotid artery isolated and ligated. Topical anaesthetic (EMLA, 5%
prilocaine and lidocaine, AstraZeneca, UK) was applied to skin incision sites prior to incision.
The internal carotid artery and the pterygopalatine artery were temporarily ligated. A 6-0 monofilament (Doccol, Sharon, MA, USA) was introduced into the internal carotid artery via an incision in the common carotid artery (endothelial-specific IL-1R1 deletion study) or via the external carotid artery (ubiquitous, neuronal-specific-, myeloid cell-specific and platelet-specific IL-1R1 deletion studies). The filament was advanced approximately 10 mm distal to the carotid bifurcation, beyond the origin of the middle cerebral artery. Relative CBF was monitored for the first 30-45 min following MCAo, during which time relative CBF had to reduce by at least 70% of pre-ischaemic values for inclusion. After 30 min of occlusion (endothelial-specific IL-1R1 deletion study) or 45 min of occlusion (ubiquitous, neuronal-specific-, myeloid cell-specific and platelet-specific IL-1R1 deletion studies) the filament was withdrawn back into the common carotid artery to allow reperfusion to take place. The wound was sutured and mice received a subcutaneous bolus dose of saline for hydration (500 µl) and a general analgesic (Buprenorphine, 0.05 mg/kg injected subcutaneously, Vetergesic, UK). Animals were kept at 26-28°C until they recovered from anaesthesia and surgery, before being transferred back to ventilated cages suspended over a heating pad with free access to mashed food and water in normal housing conditions.
Tissue processing
Animals were perfused transcardially with 0.9% saline followed by 4% paraformaldehyde (PFA) under either terminal 3% isoflurane (30% oxygen and 70% nitrous oxide gas mix) or ketaminexylazine anaesthesia. Brains were then removed and left to post-fix for 24 h either in 4% PFA or in 10% sucrose 4% PFA before being transferred either to 30% sucrose or to 10% sucrose-PBS.
After 24 h in 10% or 30% sucrose, brains were sectioned into 25-30 µm coronal sections using a sledge microtome (Bright, Cambridgeshire, UK or Leica, Germany) for subsequent Cresyl violet staining and immunohistochemistry.
Functional outcomes
Animals were assessed for neurological deficits 24 h after MCAo a using a 5-point scoring 
Laser speckle contrast imaging (LSCI)
At the end of the MCAo surgery, mice were transferred to the stereotaxic frame and LSCI measurements performed 30 min after reperfusion under isoflurane anaesthesia, using a 
Histology and immunohistochemistry
Lesion volumes were measured using Cresyl violet staining, as previously described (7 
Image analysis
Analyses for immunohistochemistry were conducted on coronal sections taken at the same co-
ordinates (approximately +1 mm anterior to bregma), and both ipsilateral and contralateral hemispheres (to the side of the brain lesion) regions were measured in each animal.
Neutrophils were counted in the middle of the striatum and in the cerebral cortex. Analysis of vascular markers (ICAM-1, VCAM-1) and Iba1 immunostaining was conducted in the penumbra region of the cortex and in the striatum. The activation states of Iba1-positive microglia were scored based on the morphology, as described previously (40) 
Statistical analysis
Sample size for experimental stroke studies were determined by a priori power calculation using G*Power 3.1.9.2 with mean differences and standard deviations based on pilot studies and previous experiments (power 80%, α 0.05). Data were assessed for normal distribution using the Shapiro-Wilk W-test in order to determine parametric or non-parametric analysis.
Lesion volume and BBB breakdown were analysed with one-way ANOVA followed by post-hoc Tukey multiple comparisons between treatments groups. Mann-Whitney test was used to analyse differences between control and IL-1R1 fl/fl Δ ChAT mice due to the lack of normality of data sets. Neurological scoring was analysed with non-parametric Mann-Whitney test (2 groups) or Kruskal-Wallis test combined with Dunn's multiple comparisons test.
Immunofluorescence data were analysed by two-way ANOVA, and post-hoc Tukey's multiple comparisons between matched hemisphere and treatment groups. Significant difference was considered for p<0.05.
Results
Brain endothelial IL-1R1 deletion reduces infarct volume, BBB permeability and improves neurological function
First, we investigated brain injury after targeted deletion of IL-1R1 from the cerebrovasculature.
IL-1R1 fl/fl Δ Slco1c1 animals ( Figure 1A ) injected with tamoxifen showed reduced IL-1R1 protein expression in cerebral blood vessels at day 7 and IL-1R1 expression was completely ablated on day 14 ( Figure 1B ). Experimental animals in this study were used at day 21 onwards.
Deletion Figure 2B ) and 55% (95% CI: 1.81 to 33.08, p=0.027) for VCAM-1 ( Figure 2D) Tamoxifen-treated IL-1R1 fl/fl mice had equivalent levels of ICAM-1 ( Figure 2B ) and VCAM-1 ( Figure 2D ) to vehicle-treated IL-1R1 fl/fl Δ Slco1c1 mice.
We have demonstrated previously that IL-1 actions on brain endothelial cells in vitro contribute to neutrophil infiltration and subsequent neurotoxicity (14) . Since our data demonstrate that brain endothelial IL-1R1 contributes to brain damage and BBB dysfunction, we next investigated the possible mechanisms underlying brain endothelial IL-1R1 deletion-induced ischaemic damage, by assessing stroke induced neutrophil infiltration after IL-1R1 deletion. signalling may alter neuronal activity and /or protective microglia neuron interactions.
Brain endothelial, but not neuronal IL-1R1 deletion improves early perfusion deficits after cerebral ischaemia
To investigate whether site-specific IL-1 actions influenced brain perfusion early enough to influence the evolution of the infarct, we assessed cerebral perfusion changes 30 min after the induction of reperfusion in three adjacent regions of interest (ROI; Figure 5A ). In the absence of There was a significant reduction in infarct size (by 22.4%, p=0.0279) and brain oedema (by 57.2%, p=0.0255) in IL-1R1 fl/fl Δ ChAT mice when compared to IL-1R1 fl/fl mice ( Figure 6A-B) .
Deletion of IL-1R1 in cholinergic cells also improved functional outcome as assessed by Garcia's composite neurological score ( Figure 6D , p=0.0263), whilst a non-significant trend for improved sensory-motor function was observed by using the Bederson score ( Figure 6C ).
Removal of IL-1R1 signalling ubiquitously or from platelets and myeloid cells does not influence brain injury after cerebral ischaemia
We chose to flox exon 5 in the il-1r1 locus to effectively eliminate all IL-1R1 isoforms in order to generate a new line of IL-1R1 fl/fl mice where the receptor is fully eliminated ( Figure 7A ).
Ubiquitous deletion of IL-1R1 was confirmed with PCR from tail samples and a lack of IL-1R1 immunoreactivity in the brain ( Figure 7B ). In spite of the complete absence of functional IL-1R1 in these mice and the marked protective effect of endothelial and neuronal IL-1R1 deletion, ubiquitous IL-1R1 KO mice subjected to cerebral ischaemia showed no difference in infarct size We also observed microglial cell activation in the peri-infarct area but this activation was not affected by deletion of IL-1R1 in the brain endothelial cells or in the absence of neuronal IL-1 signalling. As well as changes to activation state due to cerebral injury, microglia also proliferate when activated (53) . We saw no difference in the numbers of microglia between any of the treatment groups in the peri-infarct zone, which could be due to the short (24 h) survival times used in this study (51) .
In contrast, deletion of IL-1R1 in IL-1R1 fl/fl Δ Nestin mice altered microglial process coverage of neurons, which indicates changes in microglia-neuron interactions after stroke. We have demonstrated recently that microglia are key contributors to neuronal network activity changes in the injured brain in vivo and an absence of microglia leads to markedly augmented neuronal injury after stroke (42). This is likely due in part to an early protective action of microglia against excitotoxicity in the evolving penumbra (42), which is associated with increased microglial process coverage of neurons that increases with higher level of neuronal activity. These results are consistent with observations of microglial actions on excitotoxicity using repetitive supramaximal stimulation and the effect of IL-1 on microglial process convergence toward neuronal axons in brain slices (54, 55) . Increased microglial process coverage after neuronal, but not endothelial deletion of IL-1R1, could be linked to improved microglial control of neuronal activity, which should be investigated in detail in further studies.
To investigate the neurochemical phenotype of neurons that may mediate detrimental IL-1 effects via IL-1R1 signalling in the area of the brain supplied by the MCA, we chose to selectively eliminate IL-1R1 from cholinergic neurons. Cholinergic cells in the basal forebrain and the brainstem give rise to widespread innervation of the striatum (56, 57) and the cerebral cortex.
Besides the strong associations of the cholinergic system with attention, memory and cognitive function (58-63), dysfunction of cholinergic neurons is linked with a wide array of neurodegenerative disorders (64) . Atrophy of the basal forebrain cholinergic system is associated with cognitive impairment (65) and precedes Alzheimer's disease pathology (66) . shown to be vulnerable to excitotoxicity and inflammation, which may also be indicated by changes in ACh levels or cholinergic receptors described in several neurodegenerative disorders (78, 79) . Thus, IL-1-mediated actions could promote the dysfunction of cholinergic neurons via different forms of injury including increased excitoxicity and/or lead to impaired regulation of central and peripheral inflammatory processes by shaping the activity of the forebrain cholinergic system (70, 80) , which will need to be investigated in further studies.
It is widely recognised that peripheral inflammatory disorders predispose to, or exacerbate, cardiovascular (81) and cerebrovascular diseases (82) . Experimental exacerbation of ischaemic brain injury by systemic infection and CNS pathology, induced by atherosclerosis, are mediated by peripheral IL-1 (26, 51, 83) . The cell targets and mechanisms of these effects are unknown, but the brain endothelium is a key candidate, since IL-1 penetrates the brain at very low levels (84) . Circulating concentrations of IL-1 never reach high levels apart from in severe infection (85) but circulating immune cells may deliver IL-1 to the cerebrovasculature (26) , where IL-1R1 expression in the brain is highest (11) . We show, however, that although both platelets and myeloid cells produce IL-1 and contribute to brain injury after cerebral ischaemia (28, 86), IL-1 actions via IL-1R1 in these cells are not required for these effects.
Previous research found that mice lacking IL-1R1 had comparable infarct volumes to wild-type (WT) animals (87) . Since in these IL-1R1 KO mice the expression of a truncated form of IL-1R1
could not be excluded (88) 
